List view / Grid view
9 February 2015 | By Alkermes plc
Alkermes plc announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis...
9 February 2015 | By Eli Lilly and Company
Eli Lilly and Company will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015. Alfonso Zulueta, Sr. Vice President and President, Emerging Markets will participate in a fireside chat at 8:25 a.m. EST...
9 February 2015 | By GlobalData
Adam Dion, MS, GlobalData’s Healthcare Industry Analyst, says: “On 5 February 2015, just days after gaining US Food and Drug Administration (FDA) breakthrough approval for Ibrance (palbociclib) in breast cancer, Pfizer entered into an agreement to purchase generic drug maker Hospira..."
9 February 2015 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, in people with diabetic macular edema...
9 February 2015 | By Moberg Pharma
Moberg Pharma AB announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine...
9 February 2015 | By The International Longevity Centre
With demand for NHS services already under pressure, new analysis by the International Longevity Centre – UK and supported by Engage Mutual, the over-50s life cover specialists, predicts the NHS may have to support up to one million more older people with serious illnesses within the next ten years...
6 February 2015 | By Janssen EMEA
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…
6 February 2015 | By Merck
The 5 year program was kicked off successfully in Africa, India and Indonesia and will further expand to other African and Asian countries in 2015...
6 February 2015 | By Public Health England
Flu vaccination remains important for other strains that still may circulate this winter...
6 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will take part in the Leerink Swann Global Health Care Conference on Thursday, February 12, 2015, in New York...
6 February 2015 | By The Cochrane Library
The Cochrane Library recently published a review of chondroitin sulfate that confirms the efficacy and safety of this drug in the treatment of osteoarthritis...
5 February 2015 | By Eli Lilly and Company
New funding builds on a longstanding partnership to help Kenyans receive quality care...
5 February 2015 | By BIOTRONIK
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced that patient enrollment for the BIOFLOW-IV study has been completed...
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
4 February 2015 | By AstraZeneca
AstraZeneca announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City...
